We offer a subscription service with a nightly email, research reports, SMS alerts, education, group chat and more. Click here to see our offerings and plans.
- A late-stage medical device and biopharma company developing its proprietary LungFit device that generates Nitric Oxide (NO) from ambient air for the treatment of lung infections.
- XAIR is also exploring the potential of its NO system to treat acute viral pneumonia and COVID-19 (interim data is expected in Spring 2021)
- On the pharmaceutical side, XAIR is investigating its technology for the treatment of solid tumors
- Its most advanced programs are targeting in-Hospital use for PPHN and cardiac surgery as well as Bronchiolitis (combined market potential of $800M+)